Brandywine Pharmaceuticals, LLC recalls Theophylline Extended-Release Tablets
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
- Products
-
- Theophylline Extended-Release Tablets
- Where it was sold
-
Nationwide within U.S
Nationwide
- Units affected
- 1,620 100-count bottles
- About this recall
- Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10